PharmiWeb.com - Global Pharma News & Resources
16-Sep-2021

aap Implantate AG significantly raises EBITDA forecast for financial year 2021

aap Implantate AG / Key word(s): Change in Forecast/Annual Results
aap Implantate AG significantly raises EBITDA forecast for financial year 2021

16-Sep-2021 / 13:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

aap Implantate AG ("aap" or the "Company") announces that the EBITDA guidance for the financial year 2021 is increased significantly by approx. 64% up to approx. 80% to a range between EUR -2.0 million and EUR -0.7 million. This is due to lower overall operating expenses, which will be incurred to a substantially lower extent as a result of strict cost discipline, and in particular a noticeably reduced cost framework for the planned human clinical study for the antibacterial silver coating technology. The cost reduction in connection with the human study results, on the one hand, from the decision to build up important know-how internally and thus to carry out the study with a higher proportion of own work. On the other hand, after re-evaluation of all available findings and renegotiation of contracts, the total cost of the study could be significantly reduced. In addition, the COVID-19-related postponement of the start of the human clinical study to the fourth quarter of 2021 means that a lower proportion of the costs will be incurred in the current financial year 2021 than was originally planned.
 

Against the backdrop of these developments, aap adjusts the outlook for the financial year 2021 and expects EBITDA in the range of EUR -2.0 million to EUR -0.7 million (previously: EUR -5.5 million to EUR -3.5 million) based on a now narrowed sales level of EUR 12.0 million to EUR 14.0 million (previously: EUR 12.0 million to EUR 15.0 million). Excluding R&D project costs for the silver coating and resorbable magnesium implant technologies, the forecast values for EBITDA are now between EUR -1.1 million and EUR +0.2 million (previously: EUR -2.8 million to EUR -0.8 million).


 

-------------------------------------------------------------------------------------------------------------------------------------------
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

 

For queries, please contact:

aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; Email: f.franke@aap.de

16-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE000A3H2101
WKN: A3H210
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1233909

 
End of Announcement DGAP News Service

Editor Details

Last Updated: 16-Sep-2021